D. Coscas

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

Shomron Ben‐Horin, Miri Yavzori, Lior H. Katz et al. · Gut · 2010 · 205 citations

Life Sciences, Immunology, Clinical Immunology +15

Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases

Bella Ungar, Uri Kopylov, Miri Yavzori et al. · Clinical Gastroenterology and Hepatology · 2017 · 122 citations

Medicine, Pharmacology, Pharmacotherapy +17

Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies

Uri Kopylov, Yoav Mazor, Miri Yavzori et al. · Inflammatory Bowel Diseases · 2011 · 86 citations · Full text

Life Sciences, Immunology, Clinical Immunology +16

The decline of anti‐drug antibody titres after discontinuation of anti‐<scp>TNF</scp>s: implications for predicting re‐induction outcome in <scp>IBD</scp>

Shomron Ben‐Horin, Yoav Mazor, Henit Yanai et al. · Alimentary Pharmacology & Therapeutics · 2012 · 56 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +16

Multiple Antral Ulcers in Gastric Sarcoid

Zvi Fireman, A Sternberg, Y. Yarchovsky et al. · Journal of Clinical Gastroenterology · 1997 · 44 citations

Medicine, Immunology, Pathology +15